23andMe Holding Co. logo
23andMe Holding Co. (ME)
Compare

23andMe Holding Co. (ME) Average Quick Ratio

Quick Ratio

The current quick ratio for 23andMe Holding Co. (ME) is N/A as of Monday, June 15, 2026, shown against its trailing averages.

Average Quick Ratio Chart

ME Quick Ratio Averages

QUICK RATIO CURRENT

N/A

QUICK RATIO TTM

1.29

QUICK RATIO 3Y

2.30

QUICK RATIO 5Y

2.23

QUICK RATIO 10Y

2.30

QUICK RATIO 15Y

2.30

QUICK RATIO 20Y

2.30

About 23andMe Holding Co.

23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.

South San Francisco, CA
560 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Joseph Selsavage